| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|
Phase N/A 1
2 3 4 Trials | | 0 | 12345678910 |
|---|
| | | | |
|---|
| | | | |
|---|
| | | | |
|---|
| CAR19T2 T cells / Zhaotai InVivo Biomedicine | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells / Hunan Yongren Medical Innovation, Zhaotai InVivo Biomedicine | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, B7-H3 targeting CAR-TILs / Zhaotai InVivo Biomedicine | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, B7-H3 targeting TILs / Zhaotai InVivo Biomedicine | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| TGFβ targeting CAR-T cells / Hunan Yongren Medical Innovation, Zhaotai InVivo Biomedicine | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
|
